MX2019012493A - Acidos p-etoxi nucleicos para la inhibicion de igf-1r. - Google Patents

Acidos p-etoxi nucleicos para la inhibicion de igf-1r.

Info

Publication number
MX2019012493A
MX2019012493A MX2019012493A MX2019012493A MX2019012493A MX 2019012493 A MX2019012493 A MX 2019012493A MX 2019012493 A MX2019012493 A MX 2019012493A MX 2019012493 A MX2019012493 A MX 2019012493A MX 2019012493 A MX2019012493 A MX 2019012493A
Authority
MX
Mexico
Prior art keywords
igf
inhibition
nucleic acids
ethoxy
ethoxy nucleic
Prior art date
Application number
MX2019012493A
Other languages
English (en)
Spanish (es)
Inventor
Ana Ashizawa
Douglas Craig Hooper
David W Andrews
Original Assignee
Bio Path Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bio Path Holdings Inc filed Critical Bio Path Holdings Inc
Publication of MX2019012493A publication Critical patent/MX2019012493A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/345—Spatial arrangement of the modifications having at least two different backbone modifications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MX2019012493A 2017-04-19 2018-04-19 Acidos p-etoxi nucleicos para la inhibicion de igf-1r. MX2019012493A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762487425P 2017-04-19 2017-04-19
PCT/US2018/028308 WO2018195281A1 (en) 2017-04-19 2018-04-19 P-ethoxy nucleic acids for igf-1r inhibition

Publications (1)

Publication Number Publication Date
MX2019012493A true MX2019012493A (es) 2020-08-17

Family

ID=63856055

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012493A MX2019012493A (es) 2017-04-19 2018-04-19 Acidos p-etoxi nucleicos para la inhibicion de igf-1r.

Country Status (9)

Country Link
US (2) US20200038429A1 (enExample)
EP (1) EP3628003A4 (enExample)
JP (1) JP2020517645A (enExample)
KR (1) KR20200021453A (enExample)
CN (1) CN111447922A (enExample)
AU (1) AU2018254485B2 (enExample)
CA (1) CA3060090A1 (enExample)
MX (1) MX2019012493A (enExample)
WO (1) WO2018195281A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6957035B2 (ja) 2015-04-10 2021-11-02 トーマス・ジェファーソン・ユニバーシティ 対象への移植用の免疫原性拡散チャンバおよびその調製方法
EP3362563A1 (en) 2015-10-14 2018-08-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for liposomal formulation
SG11201901667TA (en) 2016-09-16 2019-03-28 Bio Path Holdings Inc Combination therapy with liposomal antisense oligonucleotides
US12234457B2 (en) 2017-04-19 2025-02-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for BCL2 inhibition
WO2018195249A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for stat3 inhibition
MX2021005168A (es) * 2018-11-02 2021-08-24 Univ Jefferson Metodos y composiciones para el tratamiento de cancer de mama usando antisentido.
US20240368247A1 (en) * 2020-12-02 2024-11-07 The Royal Institution For The Advancement Of Learning/Mcgill University Therapeutic applications of type 1 insulin-like growth factor (igf-1) receptor antagonists

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US6015886A (en) * 1993-05-24 2000-01-18 Chemgenes Corporation Oligonucleotide phosphate esters
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
US7704962B1 (en) * 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US20030180789A1 (en) * 1998-12-30 2003-09-25 Dale Roderic M.K. Arrays with modified oligonucleotide and polynucleotide compositions
EP1432724A4 (en) * 2002-02-20 2006-02-01 Sirna Therapeutics Inc RNA inhibition mediated inhibition of MAP KINASE GENES
US9150605B2 (en) * 2002-11-05 2015-10-06 Isis Pharmaceuticals, Inc. Compositions comprising alternating 2′-modified nucleosides for use in gene modulation
JP6637957B2 (ja) 2014-07-17 2020-01-29 シグニファイ ホールディング ビー ヴィSignify Holding B.V. 栽培用照明装置
JP6957035B2 (ja) * 2015-04-10 2021-11-02 トーマス・ジェファーソン・ユニバーシティ 対象への移植用の免疫原性拡散チャンバおよびその調製方法
EP3362563A1 (en) * 2015-10-14 2018-08-22 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for liposomal formulation

Also Published As

Publication number Publication date
AU2018254485A1 (en) 2019-10-31
KR20200021453A (ko) 2020-02-28
AU2018254485B2 (en) 2024-07-11
CN111447922A (zh) 2020-07-24
US20200038429A1 (en) 2020-02-06
US12472199B2 (en) 2025-11-18
JP2020517645A (ja) 2020-06-18
CA3060090A1 (en) 2018-10-25
EP3628003A4 (en) 2021-01-20
EP3628003A1 (en) 2020-04-01
WO2018195281A1 (en) 2018-10-25
US20220133775A1 (en) 2022-05-05

Similar Documents

Publication Publication Date Title
MX2016016364A (es) Terapia de combinacion con inhibidores de glutaminasa.
CY1123289T1 (el) Ενωσεις ολιγονουκλεοτιδιων για τη στοχευση του huntingtin mrna
MX2017008844A (es) Terapia de combinacion con inhibidor de acetil-coa carboxilasa (acc) para el tratamiento de enfermedad de higado graso no alcoholico.
MX2025010269A (es) Constructos de arni para inhibir la expresion de pnpla3 y metodos de uso de los mismos
MX2018002158A (es) Mí‰TODOS Y COMPOSICIONES PARA TRATAR UN TRASTORNO ASOCIADO A GEN DE PROPROTEINA CONVERTASA SUBTILISINA KEXINA (PCSK9).
CO2018003542A2 (es) Anticuerpo anti-garp
PH12019501959A1 (en) Therapeutic rna
CO2017007671A2 (es) Composiciones para modular la expresión de c9orf72
MX2020004698A (es) Exosomas que comprenden agentes terapeuticos de arn.
EA201791951A1 (ru) Продукты рилузола и их применение
CL2017002241A1 (es) Método de tratamiento de cáncer asociado con una mutación de ras
CL2021001489A1 (es) Constructos de arni para inhibir la expresión de pnpla3 y métodos de uso de estos
CL2015002571A1 (es) Composiciones y métodos para le diagnostico y tratamiento del cáncer hepático.
MX2017013802A (es) Métodos para tratar el cáncer.
MX2017005258A (es) Terapia combinada para tratamiento de enfermedad.
MX2018000981A (es) Composiciones de acido ribonucleico interferente (arni) de transtiretina (ttr) y metodos para su uso para el tratamiento o prevencion de enfermedades asociadas con transtiretina (ttr).
SV2019005822A (es) Metodos para tratar el cáncer de próstata
CR20170319A (es) Proceso para mejorar porciones de músculo y productos
CO2018004821A2 (es) Ácidos nucleicos p-etoxi para formulación liposomal
BR112019002458A2 (pt) composições e métodos para tratar câncer com depleção de arginina e agentes imuno-oncológicos
SA519410315B1 (ar) أحماض نووية p - stat3 إيثوكسي لتثبيط
UY35582A (es) COMPOSICIONES DE ARNi DE SERPINA1 Y SUS MÉTODOS DE USO
MX2017011298A (es) Métodos para tratar cáncer que albergan la pérdida hemicigota de tp53.
EA201990567A1 (ru) Комбинированная терапия с ингибиторами глутаминазы
CO2017000950A2 (es) Compuestos que comprenden oligonucleótidos modificados dirigidos a mir-103 y/o mir-107 para trastornos metabólicos